UNSPSC 51284101: Cefcapene

This classification denotes a cephalosporin antibiotic with the molecular formula C17H19N5O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4D5D3422MW, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-((2-(2-amino-4-thiazolyl)-1-oxo-2-pentenyl)amino)-8-oxo-, (6r-(6alpha,7beta(z)))- but generally known as cefcapene, which bears US NIH Compound Identifier 6436055.

UNSPSC 51284101 Cefcapene is a Commodity code that nominally covers a specific oral cephalosporin antibiotic; however, recent state and local procurement activity under this code shows little alignment with the product name. The Illinois Department of Public Health and Seminole County, Florida have posted opportunities tagged to this code, but the actual goods being procured—Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets in one case, and Naloxone plus drug deactivation systems in another—fall outside the cefcapene product class. State and local health departments and counties represent the primary issuing bodies for pharmaceutical and medical supply procurement under this code tag, though the mismatch between code assignment and actual product scope suggests either data-entry error or broad pharmaceutical-category coding at the agency level. Buyers appear to use cooperative purchasing vehicles and piggyback agreements, particularly through consortia like MMCAP Infuse, to streamline pharmaceutical procurement with fixed terms (typically 12 to 36 months) and renewal options.

Activity concentrates in Florida and Illinois based on recent postings. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback contract to Chartwell Rx LLC on August 28, 2026, through MMCAP Infuse for antibiotic tablets over a 12-month initial term with two renewal years; this was a completed award under an Invitation for Bid process, not an open solicitation. Seminole County, Florida posted an IFB (number IFB60459723LAS) on June 30, 2026, with a July 26, 2023 response date, seeking 1,900 units of Naloxone and 800 drug deactivation systems annually with quarterly deliveries and a two-year initial contract term plus one-year renewal option. Neither opportunity identified set-aside utilization or domestic-product preferences. The code shows limited recent relevant activity; the mismatch between cefcapene and the actual pharmaceutical and medical supplies being procured warrants clarification before pursuing opportunities tagged to this code.